Search

Displaying results 4201 - 4210 of 9881 in total
  1. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    +7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) Score were observed. … It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis.

  2. Drug

    Inodiftagene vixteplasmid

    go.drugbank.com/drugs/DB16017
    Investigational

    Inodiftagene vixteplasmid is a plasmid DNA vector encoding the diphtheria toxin A (dT-a) gene under transcriptional regulation of the promoter region of the human H19 gene (an imprinted maternally expressed

    Synonyms: dT-A-H19, diphtheria-toxin-A-H19
  3. Drug

    AAV-AIPL

    go.drugbank.com/drugs/DB17857
    Experimental

    Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.

  4. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    The drug made it to phase III trials before abandoned due to increased stroke. … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

  5. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.

  6. Drug

    Hyperforin

    go.drugbank.com/drugs/DB01892
    InvestigationalNutraceutical

    Hyperforin is a phytochemical generated by the plants of the Hypericum family. … One of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.

  7. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    It is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022]. … Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion.

    Synonyms: Remestemcel-L
  8. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. … [A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible

  9. Drug

    Selenious acid

    go.drugbank.com/drugs/DB11127
    Approved

    Selenium is a component of glutathione peroxidase enzyme, which protects cell components from oxidative damage due to peroxides produced during cellular metabolism [L1916]. … Selenious acid is the acid form of sodium selenite, a form of selenium [L1910]. Selenium is an essential trace element and antioxidant. It is a cofactor metabolic enzyme regulation.

    Mixtures: Formula F L W
  10. Drug

    Cefepime

    go.drugbank.com/drugs/DB01413
    ApprovedInvestigational

    Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. … The activity of cefepime against Enterobacteriaceae, _Pseudomonas aeruginosa_, and _Staphylococcus aureus_ is due to its high stability toward beta-lactamases.